Vascular cognitive impairment

Current Opinion in Neurology

Volumn 26, Issue 1, 2013, Pages 29-36

  Rincon, Fred ^a   Wright, Clinton B ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Alzhemier's disease; dementia; mild cognitive impairment; stroke

Indexed keywords

APOLIPOPROTEIN E; ENALAPRIL; HOMOCYSTEINE; INDAPAMIDE; PERINDOPRIL; RAMIPRIL;

ALCOHOL CONSUMPTION; AWARENESS; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; HEART ATRIUM FIBRILLATION; HISTOPATHOLOGY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; METABOLIC SYNDROME X; MILD COGNITIVE IMPAIRMENT; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SMOKING; TRANSIENT ISCHEMIC ATTACK; VASCULAR COGNITIVE IMPAIRMENT;

COGNITION DISORDERS; HUMANS; VASCULAR DISEASES;

EID: 84872943328     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32835c4f04     Document Type: Review

References (103)

1. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol 2007; 6:1106-1114.
2. Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement 2011; 7:61-73.
3. Gunguli M. Epidemiology of dementia. In: Abou-Saleh MT, Katona C, Kumar A, editors. Principles and practice of geriatric psychiatry. Hoboken, NJ: Wiley; 2011.
4. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37:2220-2241.
5. Leblanc GG, Meschia JF, Stuss DT, Hachinski V. Genetics of vascular cognitive impairment: the opportunity and the challenges. Stroke 2006; 37:248-255.
6. Rockwood K, Brown M, Merry H, et al. Societal costs of vascular cognitive impairment in older adults. Stroke 2002; 33:1605-1609.
7. Hachinski VC, Lassen NA, Marshall J. Multiinfarct dementia. A cause of mental deterioration in the elderly. Lancet 1974; 2:207-210.
8. Loeb C, Gandolfo C. Methodological problems of clinical trials in multiinfarct dementia. Neuroepidemiology 1990; 9:223-227.
9. Bowler JV, Steenhuis R, Hachinski V. Conceptual background to vascular cognitive impairment. Alzheimer Dis Assoc Disord 1999; 13:S30-S37.
10. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:2672-2713.
11. Gold CA, Budson AE. Memory loss in Alzheimer's disease: implications for development of therapeutics. Expert Rev Neurother 2008; 8:1879-1891.
12. O'Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003; 2:89-98.
13. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277:813-817.
14. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348:1215-1222.
15. Jeerakathil T, Wolf PA, Beiser A, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004; 35:1857-1861.
16. Petri M, Naqibuddin M, Carson KA, et al. Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. J Rheumatol 2010; 37:2032-2038.
17. Selnes OA, Royall RM, Grega MA, et al. Cognitive changes 5 years after coronary artery bypass grafting: is there evidence of late decline? Arch Neurol 2001; 58:598-604.
18. Hanly JG, Walsh NM, Fisk JD, et al. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br J Rheumatol 1993; 32:291-296.
19. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256:184-185.
20. De la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 1993; 15:146-153.
21. Riley KP, Snowdon DA, Markesbery WR. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 2002; 51:567-577.
22. Jellinger KA. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 2007; 113:349-388.
23. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34:335-337.
24. Bronge L, Bogdanovic N, Wahlund LO. Postmortem MRI and histopathology of white matter changes in Alzheimer brains. A quantitative, comparative study. Dement Geriatr Cogn Disord 2002; 13:205-212.
25. Cheung N, Mosley T, Islam A, et al. Retinal microvascular abnormalities and subclinical magnetic resonance imaging brain infarct: a prospective study. Brain 2010; 133:1987-1993.
26. Gons RAR, de Laat KF, van Norden AGW, et al. Hypertension and cerebral diffusion tensor imaging in small vessel disease. Stroke 2010; 41:2801-2806.
27. Vernooij MW, Ikram MA, Vrooman HA, et al. White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry 2009; 66:545-553.
28. Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34:1126-1129.
29. Bernick C, Kuller L, Dulberg C, et al. Silent MRI infarcts and the risk of future stroke. Neurology 2001; 57:1222-1229.
30. Elkins JS, O'Meara ES, Longstreth WT Jr, et al. Stroke risk factors and loss of high cognitive function. Neurology 2004; 63:793-799.
31. Seshadri S, Wolf PA, Beiser A, et al. Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology 2004; 63:1591-1599.
32. Longstreth WT, Jr. Brain abnormalities in the elderly: frequency and predictors in the United States (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group. JNeural Transm Suppl 1998; 53:9-16.
33. Breteler MM, van Swieten JC, Bots ML, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994; 44:1246-1252.
34. DeCarli C, Miller BL, Swan GE, et al. Predictors of brain morphology for the men of the NHLBI twin study. Stroke 1999; 30:529-536.
35. Kuller LH, Longstreth WT Jr, Arnold AM, et al. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. Stroke 2004; 35:1821-1825.
36. Schneider JA, Wilson RS, Cochran EJ, et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003; 60:1082-1088.
37. Alves de Moraes S, Szklo M, Knopman D, Sato R. The relationship between temporal changes in blood pressure and changes in cognitive function: atherosclerosis risk in communities (ARIC) study. Prev Med 2002; 35:258-263.
38. Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998; 31:780-786.
39. Swan GE, Carmelli D, Larue A. Systolic blood pressure tracking over 25 to 30 years and cognitive performance in older adults. Stroke 1998; 29:2334-2340.
40. Kramer JH, Reed BR, Mungas D, et al. Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 2002; 72:217-220.
41. Orgogozo J-M, Rigaud A-S, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834-1839.
42. Longstreth WT Jr, Bernick C, Manolio TA, et al. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998; 55:1217-1225.
43. Ruitenberg A, Skoog I, Ott A, et al. Blood pressure and risk of dementia: results from the Rotterdam Study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001; 12:33-39.
44. Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ 1996; 312:805-808.
45. Kario K, Pickering TG, Matsuo T, et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38:852-857.
46. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
47. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324:699-702.
48. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
49. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163:1069-1075.
50. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Lancet 1997; 350:757-764.
51. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (SYST-EUR) study. Arch Intern Med 2002; 162:2046-2052.
52. The SPRINT Memory and cognition IN Decreased hypertension (SPRINT-MIND). Available at http://www.sprinttrial.org/public/dspHome.cfm. [Accessed 31 October 2012].
53. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framing-ham study. JAMA 1979; 241:2035-2038.
54. McNay EC. The impact of recurrent hypoglycemia on cognitive function in aging. Neurobiol Aging 2005; 26 (Suppl. 1):76-79.
55. Cox DJ, Kovatchev BP, Gonder-Frederick LA, et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 2005; 28:71-77.
56. Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging S. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002; 51:1256-1262.
57. Korf ES, White LR, Scheltens P, Launer LJ. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 2006; 29:2268-2274.
58. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154:635-641.
59. Kalmijn S, Feskens EJ, Launer LJ, et al. Glucose intolerance, hyperinsulinae-mia and cognitive function in a general population of elderly men. Diabeto-logia 1995; 38:1096-1102.
60. Qiu WQ, Price LL, Hibberd P, et al. Executive dysfunction in homebound older people with diabetes mellitus. J Am Geriatr Soc 2006; 54:496-501.
61. Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 1998; 21:398-402.
62. Kuo HK, Jones RN, Milberg WP, et al. Effect of blood pressure and diabetes mellitus on cognitive and physical functions in older adults: a longitudinal analysis of the advanced cognitive training for independent and vital elderly cohort. J Am Geriatr Soc 2005; 53:1154-1161.
63. Xu WL, Qiu CX, Wahlin A, et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004; 63:1181-1186.
64. Areosa SA, Grimley EV. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 2002; CD003804.
65. Schipper HM. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol Aging 2011; 32:778-790.
66. Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137:149-155.
67. Notkola IL, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipo-protein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17:14-20.
68. Solomon A, Kivipelto M, Wolozin B, et al. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009; 28:75-80.
69. Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003; 163:1053-1057.
70. Haag MD, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80:13-17.
71. McGuinness B, O'Hare J, Craig D, et al. Statins for the treatment of dementia. Cochrane Database Syst Rev 2010; CD007514.
72. Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000; 20:2255-2260.
73. Waldstein SR, Katzel LI. Interactive relations of central versus total obesity and blood pressure to cognitive function. Int J Obes (Lond) 2006; 30:201-207.
74. Vieira JR, Elkind MS, Moon YP, et al. The metabolic syndrome and cognitive performance: the northern Manhattan study. Neuroepidemiology 2011; 37:153-159.
75. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation 1997; 96:1089-1096.
76. Graves AB, van Duijn CM, Chandra V, et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991; 20 (Suppl. 2):S48-S57.
77. Van Duijn CM, Havekes LM, Van Broeckhoven C, et al. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ 1995; 310:627-631.
78. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 2007; 166:367-378.
79. Rusanen M, Kivipelto M, Quesenberry CP Jr, et al. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 2011; 171:333-339.
80. Elias PK, Elias MF, D'Agostino RB, et al. Alcohol consumption and cognitive performance in the Framingham Heart Study. Am J Epidemiol 1999; 150:580-589.
81. Wright CB, Elkind MS, Rundek T, et al. Alcohol intake, carotid plaque, and cognition. The Northern Manhattan Study. Stroke 2006; 37:1160-1164.
82. Mukamal KJ, Longstreth WT Jr, Mittleman MA, et al. Alcohol consumption and subclinical findings on magnetic resonance imaging of the brain in older adults: the cardiovascular health study. Stroke 2001; 32:1939-1946.
83. Kalmijn S, van Boxtel MP, Verschuren MW, et al. Cigarette smoking and alcohol consumption in relation to cognitive performance in middle age. Am J Epidemiol 2002; 156:936-944.
84. Ruitenberg A, van Swieten JC, Witteman JC, et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002; 359:281-286.
85. Mukamal KJ, Kuller LH, Fitzpatrick AL, et al. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003; 289:1405-1413.
86. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framing-ham Study. Ann Intern Med 1999; 131:352-355.
87. Sacco RL, Anand K, Lee HS, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the Northern Manhattan Study. Stroke 2004; 35:2263-2269.
88. Bell IR, Edman JS, Selhub J, et al. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand 1992; 86:386-390.
89. Riggs KM, Spiro A 3rd, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996; 63:306-314.
90. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476-483.
91. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008; CD004514.
92. McMahon JA, Green TJ, Skeaff CM, et al. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006; 354:2764-2772.
93. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155:469-473.
94. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457.
95. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27:1760-1764.
96. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 2000; 903:457-465.
97. Ott A, Breteler MM, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997; 28:316-321.
98. Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 2010; 7:433-437.
99. Knecht S, Oelschlager C, Duning T, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29:2125-2132.
100. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:1977-1981.
101. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103:5644-5651.
102. Kim KW, Youn JC, Han MK, et al. Lack ofassociation between apolipoprotein E polymorphism and vascular dementia in Koreans. J Geriatr Psychiatry Neurol 2008; 21:12-17.
103. Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology 2005; 64:1548-1552.